Detection of Differentially Expressed Proteins of Capsulation-Resistant and Sensitive Osteosarcoma Tissue

Abstract:

The tissue samples of cisplatin-resistant and sensitive patients with osteosarcoma were obtained through chemosensitivity testing before. The typical one of cisplatin-resistant and sensitive osteosarcoma tissue samples were analyzed by two-dimensional electrophoresis and the relevant differentially expressed proteins were obtained. The sequences of differentially expressed proteins were obtained through the analysis of mass spectrometry technology to be identified comparing with protein databases. It is concluded that there are differentially expressed proteins in tissue of cisplatin-resistant and sensitive osteosarcoma.

• Periodical: Advanced Materials Research (Volumes 756-759)
• Pages: 4553-4556
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.756-759.4553
• Online since: September 2013
• Authors: Li Heng Zhang, Liang Li
• Keywords: Differentially Expressed Proteins, Electrophoresis, Osteosarcoma

References

[1] Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. J. Cancer. 115, 1531-1543, (2009).

DOI: 10.1002/cncr.24121

[2] Dorfman H D, Czerniak B. Osteosarcoma. In: Dorfman HD, Czerniak B, eds. Bone tumors, 1st edn. St Louis, MO: Mosby, 128–252, (1998).

DOI: 10.2106/00004623-199906000-00021

[3] Duffaud F, Digue L, Mercier C, etc. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. J. Eur J Cancer. 39, 2050–2057, (2003).

DOI: 10.1016/s0959-8049(03)00435-0

[4] Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. J. Int J Cancer. 77, 370-377, (1998).

DOI: 10.1002/(sici)1097-0215(19980729)77:3<370::aid-ijc11>3.0.co;2-c

[5] Saeter G, Wiebe T, Wiklund T, et al. Chemotherapy in osteosarcoma: the Scandinavian sarcoma group experience. Acta Orthop Scand Suppl, 285, 74-82, (1999).

[6] Kempf-Bielack B, Bielack SS, Jürgens H, etc. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J. J Clin Oncol, 23, 559-568, (2005).

DOI: 10.1200/jco.2005.04.063

[7] Tjalma RA. Canine bone sarcoma: estimation of relative risk as a function of body size. J. J Natl Cancer Inst., 36, 1137-1150, (1966).

[8] Bacci G, Longhi A, Fagioli F, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcom a of the extremities: 27 year experience at Rizzoli Institute, Italy [J]. Eur J Cancer, vol. 41, no. 18, 2836-28451, (2005).

DOI: 10.1016/j.ejca.2005.08.026

[9] Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer., 43, 2178-2181, (1979).

DOI: 10.1002/1097-0142(197906)43:6<2178::aid-cncr2820430603>3.0.co;2-9

[10] Scotlandi K, Serra M, Nicoletti G, etc. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. vol. 56, no. 10, 2434-2439, (1996).

[11] Wunder JS, Bell RS, Wold L, Andrulis IL. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Orthop Res. vol. 11, no. 3, 396-403, (1993).

DOI: 10.1002/jor.1100110311